Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01092546 · ClinicalTrials.gov registry record · Phase 3
Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
A Phase 3 study, sponsored by GE Healthcare.
- Terminated
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT01092546: Clinical Trial Phase 3 study, sponsored by GE Healthcare.
NCT01092546 is a Phase 3 study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 12 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01092546, a Phase 3 study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
To determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples obtained from subjects during shunt placement for NPH.
Primary Outcome
The level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples obtained during shunt placement in patients who have Normal Pressure Hydrocephalus (NPH). The quantitative estimates of brain uptake of \[18F\]flutemetamol (SUVR) will be made from the analysis of PET images.
Interventions
- DRUG [18F]Flutemetamol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Why NCT01092546 stopped before completion
NCT01092546 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which [18F]Flutemetamol is the first listed.
NCT01092546 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01092546 about?
NCT01092546 is a clinical study titled "Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus". To determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples obtained from subjects during shunt placement for NPH.
What is the current status of trial NCT01092546?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2010-03. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01092546?
The interventions under investigation include: [18F]Flutemetamol (DRUG).
Who is sponsoring clinical trial NCT01092546?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01092546's enrollment target sits among peer trials
12 1984th of 2000 higher than 12 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia